Posted 25 April, 2007 - 14:54 by steve
Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery
New NICE guide line : April 2007
[url=http://www.nice.org.uk/CG46]Click here[/url]
Posted 15 April, 2007 - 11:17 by steve
My consultant neurologist normally prescribes the patients with stroke: Aspirin, Ramipril,Statin.This ESPS-2 shows there is a benefit of adding dipyridamole. It was done in 1988. so there should be more research data somewhere.
[b]European Stroke Prevention Study 2 (ESPS-2):[/b]
After doing randomised, double-blind, placebo-controlled trial of 6602 patients, it was discovered that the 24-month stroke rate was 12.9% in the aspirin-alone group, 13.2% in the dipyridamole-alone group, 9.9% in the combination group and 15.8% in the placebo group.
Stroke risk was significantly reduced by 18.1% in the aspirin-alone group, by 16.3% in the dipyridamole-alone group, and by 37.0% in the combination group compared to the placebo group. The results regarding the endpoint of stroke or death were similar but there was no significant difference among the groups for the endpoint of death .
[url=http://www.ncbi.nlm.nih.gov]source[/url]
Posted 12 February, 2007 - 12:39 by steve
This is the guide lines for Early Management of Suspected Bacterial Meningitis and Meningococcal Septicaemia in Immunocompetent Adults
[url=http://www.britishinfectionsociety.org/Adult_men_early_poster%202004.pdf]Click here[/url]
Posted 12 February, 2007 - 12:05 by steve
Clinical management of patients with an
influenza-like illness during an influenza pandemic
Provisional guidelines from the
British Infection Society
British Thoracic Society
Health Protection Agency
in collaboration with the Department of Health
Version 11, updated on 2 October 2006
[url=http://www.britishinfectionsociety.org/Pandemic%20guidelines%202007.pdf]Guidelines[/url]
Posted 31 January, 2007 - 17:21 by steve
This is not exciting but interesting topic. I think. You may check
[url=http://www.onmedica.net/content.asp?t=2&c=4462&pid=84cdcccdcccec6c9bbd2c8bccfcfd2cbbbbdced2c6bbc6bcd2becfcebecdbac8beccb9c6c882]here[/url]
Posted 30 January, 2007 - 19:09 by steve
| Age ≥ 65 years? |
1 |
| > 3 Risk Factors for CAD? |
1 |
| Known CAD (stenosis ≥ 50%)? |
1 |
| ASA Use in Past 7d? |
1 |
| Severe angina (≥ 2 episodes w/in 24 hrs)? |
1 |
| ST changes ≥ 0.5mm? |
1 |
| + Cardiac Marker? |
1 |
Risk Factors:
Posted 30 January, 2007 - 12:58 by steve
Postoperative gemcitabine significantly delayed the development of recurrent disease after complete resection of pancreatic cancer compared with observation alone. These results support the use of gemcitabine as adjuvant chemotherapy in resectable carcinoma of the pancreas.
[url=http://jama.ama-assn.org/cgi/content/abstract/297/3/267]Full article on JAMA[/url]
Posted 30 January, 2007 - 12:54 by steve
The main source of Streptococcus suis is pig across the world.It can be spread from sick or carrier pig to human who has a close contact with it.The organism causes meningitis, septicaemia, endocarditis, arthritis, and septic shock in both hosts and mortality is high. REF:
[url=http://www.thelancet.com/journals]http://www.thelancet.com/journals[/url]
Posted 9 January, 2007 - 14:31 by steve
Many consider that Proton pump inhibitors (PPIs) may interfere with calcium absorption through induction of hypochlorhydria but they also may reduce bone resorption through inhibition of osteoclastic vacuolar proton pumps.After doing the controlled trial on 13 556 hip fracture cases and 135 386 controls, conculstion is "Long-term PPI therapy, particularly at high doses, is associated with an increased risk of hip fracture."
Full article @ http://jama.ama-assn.org/cgi/content/abstract/296/24/2947
Posted 9 January, 2007 - 14:25 by steve
[b]Effects of Continuing or Stopping Alendronate After 5 Years of Treatment[/b]
Women who discontinued alendronate after 5 years showed a moderate decline in BMD and a gradual rise in biochemical markers but no higher fracture risk other than for clinical vertebral fractures compared with those who continued alendronate. These results suggest that for many women, discontinuation of alendronate for up to 5 years does not appear to significantly increase fracture risk. However, women at very high risk of clinical vertebral fractures may benefit by continuing beyond 5 years.
Full Article on JAMA @
http://jama.ama-assn.org/cgi/content/abstract/296/24/2927
